Literature DB >> 1650210

Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione.

H Fujisaki1, H Shibata, K Oketani, M Murakami, M Fujimoto, T Wakabayashi, I Yamatsu, M Yamaguchi, H Sakai, N Takeguchi.   

Abstract

A substituted benzimidazole ([4-(3-methoxypropoxy)-3-methylpyridine-2-yl]methylsulfinyl)- 1H-benzimidazole sodium salt (E3810), is a gastric proton pump (H+, K(+)-ATPase) inhibitor. E3810 and omeprazole inhibited acid accumulation dose dependently as measured with aminopyrine uptake in isolated rabbit gastric glands, their IC50 values being 0.16 and 0.36 microM, respectively. The addition of exogenous reduced glutathione (GSH) to the gland suspension reactivated dose dependently the acid secretion which had been inhibited by 2 microM E3810 or omeprazole as a function of the incubation time. Furthermore, GSH at 1 and 3 mM reversed the antisecretory effect of E3810 more quickly than it did that of omeprazole. The antisecretory effect of E3810 was slightly greater than that of omeprazole in histamine-stimulated fistula dogs in vivo. The duration of the antisecretory activity of E3810 at concentrations of 2 and 4 mg/kg was shorter than that of omeprazole at the same concentrations in pentagastrin-stimulated fistula dogs. The reversal of the antisecretory activity of the inhibitors in dogs is suggested to be due to the action of endogenous extracellular GSH, in addition to de novo synthesis of the proton pump, because bullfrog gastric mucosae were found in the present study to secrete GSH into the mucosal solution at the rate of about 0.25 nmol/min/g tissue.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650210     DOI: 10.1016/0006-2952(91)90719-l

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Rabeprazole: quest for the best PPI.

Authors:  Kentaro Sugano
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

2.  Effects of antisecretory agents on angiogenesis during healing of gastric ulcers.

Authors:  Masumi Akimoto; Hiroshi Hashimoto; Mutsuo Shigemoto; Atsushi Maeda; Katsuko Yamashita
Journal:  J Gastroenterol       Date:  2005-07       Impact factor: 7.527

3.  Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Jing Xu; Susumu Tazuma; Yoko Horikawa; Masuo Nakamura
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

Review 4.  Efficacy of rabeprazole once daily for acid-related disorders.

Authors:  F Lanza; K D Bardhan; C Perdomo; R Niecestro; J Barth
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

5.  Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes.

Authors:  Masatomo Miura; Shigeru Satoh; Hitoshi Tada; Tomonori Habuchi; Toshio Suzuki
Journal:  Eur J Clin Pharmacol       Date:  2005-12-31       Impact factor: 2.953

Review 6.  Rabeprazole.

Authors:  A Prakash; D Faulds
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

7.  Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.

Authors:  Masatomo Miura; Hideaki Kagaya; Hitoshi Tada; Tsukasa Uno; Norio Yasui-Furukori; Tomonori Tateishi; Toshio Suzuki
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

Review 8.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

9.  Synthesis of a DOTA (Gd3+)-conjugate of proton-pump inhibitor pantoprazole for gastric wall imaging studies.

Authors:  Ghulam M Maharvi; Adil E Bharucha; Abdul H Fauq
Journal:  Bioorg Med Chem Lett       Date:  2012-06-23       Impact factor: 2.823

10.  Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000.

Authors:  Adam J Smolka; James R Goldenring; Sandeep Gupta; Charles E Hammond
Journal:  BMC Gastroenterol       Date:  2004-02-10       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.